Single Dose Monurol for Treatment of Acute Cystitis

• Status: Unknown status
• Trial end date: 2018-05-30
• Target enrollment: 0
• Participant gender: Female

Summary

Urinary tract infecton (UTI) is a very common problem in young healthy women, afflicting approximately one-half of women by their late 20's. One of the most common antibiotics used to treat UTIs is Trimethoprim-sulfa (TMP-SMX), usually for total of three days. However, concerns about increased antibiotic resistance have led to increased interest in studying other antibiotics for UTI.

An alternative antibiotic which is also FDA approved for the treatment of UTIs is fosfomycin (Monurol). The effectiveness of fosfomycin in curing UTIs when given as a single dose is not well studied. The purpose of this research study is to determine what the cure rates are with a single dose of fosfomycin versus the more standard 3-day course of TMP-SMX.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Treatments: Fosfomycin

Criteria

Inclusion Criteria:

• Non pregnant women in good health with symptoms of acute cystitis for less than 7 days

Exclusion Criteria:

• Pregnant, lactating, or not regularly contracepting

• History of chronic conditions such as diabetes

• Known anatomic abnormalities of the urinary tract

• Use of prophylactic antibiotics

• History of allergy or intolerance to any of the study drugs

• Recent (> 2 weeks)exposure to oral or parenteral antimicrobial

• History of UTI in previous 1 month